US20020177626A1 - Treatment of sleep disturbances - Google Patents

Treatment of sleep disturbances Download PDF

Info

Publication number
US20020177626A1
US20020177626A1 US10/046,727 US4672702A US2002177626A1 US 20020177626 A1 US20020177626 A1 US 20020177626A1 US 4672702 A US4672702 A US 4672702A US 2002177626 A1 US2002177626 A1 US 2002177626A1
Authority
US
United States
Prior art keywords
composition
sleep
diphenhydramine
ibuprofen
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/046,727
Other languages
English (en)
Inventor
Graham Cook
Todd Koch
David Giamalva
Justin Bianco
James Fort
Geraldine Doyle
Steven Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22997281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020177626(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US10/046,727 priority Critical patent/US20020177626A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COOPER, STEVEN, DOYLE, GERALDINE, BIANCO, JUSTIN, COOK, GRAHAM D., FORT, JAMES J., GIAMALVA, DAVID H., KOCH, TODD S.
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COOPER, STEVEN, DOYLE, GERALDINE, BIANCO, JUSTIN, COOK, GRAHAM D., FORT, JAMES J., GIAMALVA, DAVID H., KOCH, TODD S.
Publication of US20020177626A1 publication Critical patent/US20020177626A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOYLE, GERALDINE
Priority to US12/082,342 priority patent/US8263647B2/en
Priority to US13/584,054 priority patent/US8883849B2/en
Priority to US14/504,159 priority patent/US9155718B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • This invention relates to the treatment of sleep disturbances.
  • the invention further relates to the treatment of sleep disturbances associated with pain, including, for example, sleep disturbances resulting in a shortened sleep duration.
  • Sleep disturbances associated with pain are especially problematic. Individuals suffering from pain-associated sleep disturbances often have great difficulty staying asleep (sleep duration), and hence getting enough rest during the night. Sleep duration is very important to the physical and mental health of the individuals involved. Because so many individuals suffer from pain-associated sleep disturbances, especially shortened sleep duration, there is a need for a medication to treat these conditions.
  • pain-associated sleep disorders we mean difficulties falling asleep (i.e., longer time until patient falls asleep) and difficulties saying asleep (i.e., waking too early, before a full night sleep), where either or both of these difficulties are present with or exacerbated by bodily pain, including, but not limited to headache, muscle aches and pain, sore throat, sinus pain, menstrual cramps, back pain, toothache, arthritis.
  • Ibuprofen a propionic acid derivative nonsteroidal anti-inflammatory drug (NSAID)
  • NSAID nonsteroidal anti-inflammatory drug
  • Ibuprofen is one of the most extensively studied and widely used drugs. It has been estimated that ibuprofen has been used to treat over 100 million patients in at least 100 countries throughout the world. Ibuprofen a very widely used drug in the world.
  • the NSAID ibuprofen has the following chemical structure:
  • ibuprofen About 80% of an oral dose of ibuprofen in humans is absorbed from the GI tract. Following oral administration, peak serum concentrations are reached within 1 or 2 hours, for suspensions and tablets, respectively. The plasma half-life of ibuprofen has reported to be about 2 hours.
  • the recommended nonprescription dose of ibuprofen for adults is 200 mg every 4 to 6 hours while symptoms persist. If the symptoms do not respond to 1 tablet (200 mg), then 2 tablets can be used. However, no more than 6 tablets should be taken in 24 hours unless directed by a physician. Higher levels of ibuprofen can be used for a prescription product, yielding a dose of 600 or 800 mg every 4 to 6 hours.
  • Ibuprofen has not previously been known to improve sleep. In fact, quite the opposite, ibuprofen has been shown in some studies of patients not suffering from pain to hinder sleep. Murphy et al., “Nonsteroidal Anti-Inflammatory Drugs Affect Normal Sleep Patterns in Humans,” Physiology & Behavior 55:1063-1066(1994). Ibuprofen has been shown to increase the number of awakenings and percentage of time spent in stage wake, and decrease sleep efficiency. Ibuprofen has also been shown to delay the onset of deeper stages of sleep. Ibuprofen was thought to have this effect by decreasing prostaglandin synthesis, reducing melatonin synthesis, and changing body temperature. Id. Other studies indicate that ibuprofen has no impact on sleep. Gengo, “The Effects of Ibuprofen on Polysomnographic and Subjective Measures of Sleep in Healthy Adults,” J. Clin. Pharmacol. 36:859 (1996).
  • Diphenhydramine hydrochloride (2-(diphenylmethoxy)-N,N-dimethylethylamine) is an ethanolamine H 1 blocking agent. It antagonizes histamine effects on receptor sites. Diphenhydramine has sedative, antiemetic, anticholinergic, anti-motion sickness, antitussive, CNS excitation and CNS depression, and local anesthetic properties as well. Diphenhydramine hydrochloride and diphenhydramine citrate, two common forms, have the following chemical structures:
  • the drugs in this group are potent and effective H 1 blockers that possess significant antimuscarinic activity and have a pronounced tendency to induce sedation.
  • conventional doses about half of those who are treated with drugs in this class experience somnolence.
  • Diphenhydramine has been primarily used for its antihistamine properties, but it has also been used for its somnolent effect and for treatment of motion sickness. There have also been some reports of weak analgesic effects.
  • Diphenhydramine is well absorbed following oral administration. Following oral administration of a single dose of diphenhydramine, the drug appears in plasma within 15 minutes, and peak plasma concentrations are attained within 1.5 to 4 hours.
  • the usual dose of diphenhydramine as a nighttime sleep aid is 50 mg of diphenhydramine hydrochloride, or an equivalent 76 mg diphenhydramine citrate.
  • diphenhydramine is well-known as a nighttime sleep aid, there exists a need for improved medications for the treatment of sleep disturbances, and in particular, pain-associated sleep disturbances.
  • ibuprofen and diphenhydramine not only is effective in the treatment of pain, but also is effective in the treatment of sleep disturbances, especially in addressing the problem of shortened sleep duration.
  • ibuprofen and diphenhydramine have the potential for negative interaction in a pharmaceutical composition.
  • the present invention provides a composition and a method of making the composition for the treatment of pain-associated sleep disturbances comprising ibuprofen and diphenhydramine in amounts effective to treat a pain associated sleep disturbance or wherein the composition is sufficiently chemically and physically stable.
  • Another embodiment of the invention provides a composition for the treatment of pain-associated sleep disturbances comprising ibuprofen and diphenhydramine, wherein the composition is formulated to avoid the risk of drug interaction.
  • the invention also provides a method of treating patients with pain-associated sleep disturbances.
  • compositions comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance.
  • Another embodiment of the present invention provides compositions comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the composition is a bilayer tablet, bilayer caplet, or soft gelatin capsule.
  • Another embodiment of the present invention provides methods for treating a patient suffering from a sleep disturbance comprising administering the composition of the invention and allowing the composition to treat the sleep disturbance.
  • a further embodiment of this invention provides a composition for the treatment of pain-associated sleep disturbances comprising ibuprofen and diphenhydramine, wherein the pain-associated sleep disturbances include difficulties falling asleep and difficulties staying asleep.
  • FIG. 1 This figure shows the duration of sleep results for Study A.
  • FIG. 2 This figure shows the nurse observed sleep latency results from Study A. Both the ibuprofen and combination groups were significantly better than the diphenhydramine and placebo groups.
  • FIG. 3 This figure shows the mean SPRID3 scores for Study A.
  • FIG. 4 This figure shows the cumulative percent of patients asleep for Study A.
  • FIG. 5 This figure shows the duration of sleep data for Study B.
  • FIG. 6 This figure shows the cumulative percent of patients asleep for Study B.
  • FIG. 7 This figure shows the mean SPRID2 scores for Study B.
  • FIG. 8 This figure shows the nurse observed sleep latency results for Study B.
  • FIG. 9 This figure shows the ease of falling asleep data for Study B.
  • FIG. 10 This figure shows the data from the global evaluation of the study medication as a sleep aid for Study B.
  • FIG. 11 This figure shows the PRID scores for Study B.
  • FIG. 12 This figure shows the global evaluation of the study medication as a pain reliever for Study B.
  • FIG. 13 This figure shows the time to rescue medication for any reason for Study C.
  • FIG. 14 This figure shows the duration of sleep data for Study C.
  • FIG. 15 This figure shows the cumulative percent asleep by 60 minutes for Study C.
  • FIG. 16 This figure shows the SPRID2 scores for Study C.
  • FIG. 17 This figure shows the nurse observed sleep latency data for Study C.
  • FIG. 18 This figure shows the ease of falling asleep data for Study C.
  • FIG. 19 This figure shows the global evaluation of the study medication as a sleep aid data for Study C.
  • FIG. 20 This figure shows PRID scores for Study C.
  • FIG. 21 This figure shows the global evaluation of the study medication as a pain reliever data for Study C.
  • FIG. 22 This figure shows the time to rescue medication for any reason data for Study C.
  • FIG. 23 This figure shows the duration of sleep data for Study D.
  • FIG. 24 This figure shows the cumulative percent of subjects asleep by 60 minutes for Study D.
  • FIG. 25 This figure shows the mean SPRID2 scores for Study D.
  • FIG. 26 This figure shows another representation of the SPRID2 scores for Study D.
  • FIG. 27 This figure shows the mean PRID scores overtime for Study D.
  • FIG. 28 This figure shows the duration of sleep data from pooling data.
  • FIG. 29 This figure shows the time to rescue medication data from pooling data.
  • ibuprofen and diphenhydramine synergistically provides for both an effective pain treatment and an effective treatment for sleep disturbances, including pain-associated disturbances such as shortened sleep duration.
  • the resulting combination yields a somnolent effect which is greater than that which can be attributed to the diphenhydramine alone.
  • This discovery is also surprising because ibuprofen is known to be effective at these doses for only 4 to 6 hours at the doses of the present invention, whereas the observed sleep duration effect from the administration of the composition of the present invention continued for notably longer periods of time.
  • composition of the present invention can be provided to a patient as ibuprofen and diphenhydramine, or alternatively either or both the ibuprofen or diphenhydramine can be provided to a patient in a prodrug form, which is metabolized in the patient's body into ibuprofen or diphenhydramine, respectively.
  • Ibuprofen dosages for use in the present invention range from 50 mg to 800 mg, from 100 mg to 800 mg, from 200 mg to 600 mg, from 200 mg to 400 mg, or 200 mg.
  • Diphenhydramine HCl dosages for use in the present invention range from 12.5 mg to 100 mg, from 25 mg to 75 mg, from 25 mg to 50 mg, or 25 mg.
  • Diphenhydramine citrate can also be used in the present invention, at corresponding levels.
  • 38 mg of diphenhydramine citrate is equivalent to 25 mg diphenhydramine HCl; the correlation between these two compounds is well known in the art.
  • diphenhydramine citrate dosages for use in the present invention range from 19 mg to 76 mg, from 38 mg to 76 mg, or 38 mg. While precise numbers for the diphenhydramine citrate are provided here and in the claims, it is not intended that these numbers be exact when determining infringement under the doctrine of equivalents. These specific dosages were chosen as they correlate to the amounts provided for the HCl salt of diphenhydramine, according to the differences in molecular weight between the compounds, and reasonable equivalents are still contemplated.
  • the dosages can be adjusted to take into account the weight of the patient and the intensity of the pain associated sleep disturbance. For example, higher dosages can be used for a more intense or problematic pain associated sleep disturbance, or for a patient who weighs more than average. Lower doses can be used for a milder problem or for a patient who weighs less than average. Lower doses can also be administered to children, the elderly, or those sensitive to medication.
  • the desired dose of ibuprofen and diphenhydramine can be included in either in a single pharmaceutical dosage unit (e.g., a tablet or capsule) or can be divided into multiple pharmaceutical dosage units (e.g., the desired doses divided into two or more tablets or capsules).
  • dose thus, means the total amount of an active ingredient given to a patient at one time. Multiple units are considered to be in the same dose if they are given at the same time or within a half an hour period. Additional units given later, such as after the patient continues to suffer from symptoms and realizes the first dose was not sufficient, are considered to be additional doses.
  • One, two or more dosage units may be given, depending upon whether the patient responds to one dosage unit and depending on other factors including the age and size of the patient, and the intensity of the problem for treatment. It is anticipated that the dosages will be such that a patient will typically take one dose, or two doses if needed.
  • ibuprofen and diphenhydramine are administered in a single pharmaceutical composition, steps should be taken to ensure that the ibuprofen and diphenhydramine do not have a chemical interaction with each other.
  • ibuprofen has an acidic moiety (—COOH) and diphenhydramine has a basic moiety (—N(CH 3 ) 2 )
  • An ion pair or salt could, thus, be formed.
  • Such an interaction creates a more nonpolar composition, which may have different dissolution characteristics and absorption profile in the body.
  • Such changes in a pharmaceutical composition may be highly undesirable, due to unpredictability of effect.
  • Different forms of diphenhydramine may interact more or less with ibuprofen. Current tests show that the HCl form is much more prone to interaction than the citrate form.
  • inventive composition may be administered with acceptable pharmaceutical carriers, excipients, or diluents, selected for the intended route of administration and the active ingredients. It is within the skill of one of ordinary skill in the art to identify carriers that are useful for oral administration. These pharmaceutical carriers, excipients, and diluents are listed in the USP pharmaceutical excipients listing. USP and NF Excipients, Listed by Categories, p. 2404-2406, USP 24 NF 19, United States Pharmacopeial Convention Inc., Rockville, Md. (ISBN 1-889788-03-1).
  • One formulation is a bilayer tablet or caplet that separates the ibuprofen and diphenhydramine from each other in distinct regions of the tablet or caplet. This physical separation reduces the possibility and/or amount of interaction between the diphenhydramine and ibuprofen.
  • PEG-containing soft gelatin capsule also called “liquigelTM” or “liquid gel”.
  • PEG 600 can be used in the soft gelatin capsule, as can other formulations such as, but not limited to, PEG 400 and PEG 800.
  • the bilayer tablet or caplet can be a two layer tablet or caplet that is formed by pressing one half of the tablet or caplet first, and then pressing the second half of the tablet or caplet onto it.
  • other separation tablets can be prepared according to the invention.
  • a tablet within a tablet (compression core tablet) can be prepared.
  • Either the ibuprofen or diphenhydramine layer could instead be compressed as a first tablet, with the other layer being compressed on its outside as an outer tablet layer.
  • one of the active ingredients could be incorporated into a coating solution which can be sprayed onto a core tablet or caplet containing the other active ingredient.
  • Either ibuprofen or diphenhydramine could be used in the coating, with the other in the core.
  • the particles of one or both drugs could be coated with a suitable barrier material, and then prepared into a tablet or capsule.
  • bilayer tablet or caplet contains 200 mg ibuprofen and 38 mg diphenhydramine citrate as the active ingredients.
  • Inactive ingredients may include any of the following calcium stearate, croscarmellose sodium, glyceryl behenate, lactose, microcrystalline cellulose, silicon dioxide colloidal, sodium lauryl sulfate, sodium starch glycolate, corn starch, preglatinized starch, starch, stearic acid, and coloring and ink ingredients.
  • Other inactive tableting ingredients would be recognized by the skilled artisan.
  • This bilayer caplet shows improved dissolution, better appearance, and minimizes any undesired interaction between the active ingredients. This reduces the potential for eutectic formation and liquefaction, which may impact the appearance (causing a mottled, pitted surface), accelerate degradation, and affect dissolution.
  • One embodiment of the soft gelatin capsule composition contains 200 mg ibuprofen and 25 mg diphenhydramine HCl as the active ingredients.
  • Inactive ingredients may include colors to give the soft gelatin capsule a pleasing appearance (e.g., D&C Red No. 33 and/or FD&C Blue No. 1), gelatin, polyethylene glycol 600 (low aldehyde), potassium hydroxide, purified water USP, ANDRISORB 85/70TM (an aqueous solution of D-sorbitol and sorbitans).
  • Fractionated coconut oil, lecithin, and VM&P naphtha may also used as a processing aid, but do not remain in the soft gelatin capsule to any significant amount in the final formulation because these processing aids are essentially removed during the washing of the final soft gelatin capsule product, prior to bulk packaging.
  • This composition is usually administered before bedtime in order to have the surprising somnolent effect.
  • the composition can also be administered during the day if the patient wishes to sleep during the day. Often, the composition should be administered from 90 minutes before bedtime to immediately before bedtime. For many applications of the present invention, the composition should be administered from 45 minutes before bedtime to 15 minutes before bedtime. In many case, it has been found that the composition should be administered 30 minutes before bedtime.
  • One or two dosage units can be taken. If two dosage units are to be taken, they can be taken at the same time, or one dosage unit can be taken with a second dosage unit taken later if needed.
  • the dosage depends on the severity of the condition, the size and age of the patient, and the response of the individual to treatment.
  • each dosage unit may contain 200 mg ibuprofen and 25 mg diphenhydramine HCl (or its equivalent of 38 mg diphenhydramine citrate).
  • the beneficial impact of the combination treatment relies on the rapid impact of ibuprofen due to its pharmacokinetic profile, and continuing effects of both the ibuprofen and diphenhydramine. It was surprisingly discovered that ibuprofen continued to have an impact towards the end of the night's sleep, as ibuprofen plasma levels typically drop significantly after 4 to 6 hours.
  • the combination soft gelatin capsule was prepared as follows. First, the fill solution was prepared. The potassium hydroxide NF (41.011 kg) was dissolved in water (34.603 kg) with the aid of a Cowels mixer (a large mixing vessel with a propeller-type mixer available from Morehouse-Cowles, Fullerton, Calif.) and was covered. The solution was blanketed with nitrogen while covered. The diphenhydramine hydrochloride (40.050 kg) was dissolved in water (46.138 kg) with the aid of a Cowels mixer. The polyethylene glycol 600 (200.250 kg) was then added with the aid of the Cowels mixer and the mixture was covered. The solution was blanketed with nitrogen while covered.
  • a Hicks reactor (a propeller-type mixer that operates under negative pressure to minimize air entrapment, available from Hicks Equipment, Louisville, Ky.) was then used.
  • the Hicks reactor was flushed with nitrogen, and then the vacuum on the reactor was pulled.
  • the polyethylene glycol 600 (326.808 kg) was added and the ibuprofen (320.400 kg) was added and mixed under vacuum.
  • the potassium hydroxide solution was added to the ibuprofen dispersion and was mixed under vacuum until uniform. The temperature was maintained between 75 and 125° F.
  • the diphenhydramine hydrochloride solution was added to the ibuprofen/potassium hydroxide/polyethylene glycol solution in the Hicks Reactor and was mixed under vacuum.
  • the fill solution was allowed to deaerate under vacuum for minutes or more.
  • the Hicks Reactor was pressurized to 10-15 psi and the fill solution was passed through a 77-micron filter into appropriately labeled containers. The containers were covered and blanketed with nitrogen.
  • the gelatin was prepared. One hundred percent bone gelatin was used; this is preferable to a mixture of bone and skin gelatin because capsules made with pure bone gelatin are less likely to stick together. According to standards established by R P Scherer, Water and ANDRISORBTM were added to a low energy mixing melter, available from Hicks Equipment, Louisville, Ky. The gelatin was vacuum transferred to the melter, while the mixture was slowly agitated and heated under vacuum until melted. The melted gelatin mixture was transferred into a heated stainless steel gel receiver. The coloring agents were added to the melted gelatin solution and blended until uniform using an R P Scherer high speed blender, R P Scherer, St. Moscow, Fla.
  • the product was encapsulated.
  • the R P Scherer softgel machine available from R P Scherer, St. Russia, Fla. was used to make a gelatin ribbon.
  • the product name was applied to the wet gelatin ribbons by direct transfer of ink from a FLEXOTM plate roll embossed with the product logo.
  • the fill solution was encapsulated within a gelatin shell using a rotary die soft gelatin capsule encapsulation apparatus fitted with a size 12 oval die.
  • the soft gelatin capsules were processed to completion.
  • the soft gelatin capsules were passed through a rotary-tumbler dryer, for 125 minutes at 90° F. and 15-30% relative humidity.
  • the soft gelatin capsules were spread onto shallow drying trays and allowed to air dry for approximately 10 to 14 days.
  • the soft gelatin capsules were then optionally stored in deep holding trays.
  • the softgels were subject to a very short wash with VM&P naphtha using a R P Scherer washer.
  • the soft gelatin capsules were then complete and ready for counting, storage, or final packaging. To retain the color of the capsules, they were kept away from light as much as possible. For example, the capsules can be packaged in opaque blisters.
  • the final soft gelatin capsule has the following composition per dose.
  • TABLE 1 Soft Gelatin Capsule Composition Ingredient Amount (mg/dose) Ibuprofen USP 200 Diphenhydramine HCl USP 25 D&C Red No. 33 0.0113 FD&C Blue No. 1 0.0170 Polyethylene Glycol 600 329 NF, low aldehyde Potassium Hydroxide NF 25.6 Purified Water 50.4 ANDRISORB 85/70 TM 93.4 Gelatin NF 164
  • the bilayer caplet was prepared as followed.
  • the diphenhydramine compression mix was prepared as a dry blend direct compression formulation.
  • Diphenhydramine citrate (59.28 kg), sodium starch glycolate (4.68 kg), FD&C blue #2 color (0.086 kg), Microcrystalline Cellulose NF (EMCOCELTTM 50 M) (94.61 kg), silicon dioxide colloidal (AEROSILTM), and starch pregelatinized 1551 (34.32 kg) were passed through a Kason sifter available from Kason Corp., Millburn, N.J. equipped with a #10 mesh screen into a Diosna P1000.
  • the Diosna P1000 is a high energy mixer and granulator, which is available from Servo-Lift, Rockaway, N.J. These materials were blended for one minute with the rotor on low and chopper on high, followed by the rotor on low for six minutes (no chopper). Glyceryl behenate (COMPRITROLTM) (4.69 kg) was passed through a #30 mesh screen and passed into the Diosna bowl through a Kason equipped with a #10 screen. The Diosna was mixed on low speed (rotor only) for three minutes. The contents of the Diosna was then discharged into conical bins, transferred into a FLO-BINTM, available from Flo-Bin, Birmingham, England, and blended for one minute.
  • Glyceryl behenate (COMPRITROLTM) (4.69 kg) was passed through a #30 mesh screen and passed into the Diosna bowl through a Kason equipped with a #10 screen.
  • the ibuprofen compression mix was manufactured through a wet granulation process.
  • the ibuprofen USP (206 kg), croscarmellose sodium (5.15 kg), starch pregelatinized NF-1551 (19.4 kg), and corn starch NF (81.3 kg) were passed through the Kason sifter equipped with a #4 mesh screen into the Diosna P1000 bowl.
  • the silicon dioxide colloidal NF (AEROSILTM) (1.03 kg) was added to the Diosna bowl and mixed with the rotor and chopper on high for two minutes.
  • the rotor and chopper were set to low, and the granulating liquid (water (115 L)) was added.
  • the batch was mixed on low (rotor and chopper) for two minutes, then switched to high (rotor and chopper) until an appropriate end point was reached (2-10 minutes), through visual inspection or by using a power cell.
  • the end point was 13% KW change in the power cell reading from the initial KW reading at the onset of high/high granulation.
  • the wet granulation was discharged from the Diosna and passed through a #4 mesh screen into an AEROMATICTM T-8 fluid bed bowl and available from Niro Pharmasystems, Columbia, Md., and dried until an appropriate end-point has been achieved (1.5-2.5% moisture content).
  • the dried granulation was then milled through a Frewitt unit equipped with a #16 mesh screen and collected in a 1200 liter FLO-BINTM.
  • Silicon dioxide colloidal NF (AEROSIL 200TM) (0.618 kg), sodium lauryl sulfate LX 100 NF (0.495 kg), and starch purity 826 National NF (7.11 kg) were combined, passed through a #30 mesh screen, and transferred to the FLO-BINTM.
  • the croscarmellose sodium (5.10 kg) was added to the FLO-BINTM, which was blended for 20 minutes at 17 RPM.
  • the stearic acid NF powder 1.82 kg was passed through a #30 mesh screen, added to the FLO-BINTM, and blended for four minutes at 17 RPM.
  • the ibuprofen compression mix and the diphenhydramine compression mix were then compressed together as bilayer caplets, each layer containing an individual active ingredient.
  • the ibuprofen layer (318.6 mg total weight per dose) was compressed as the first layer, while the diphenhydramine layer (220 mg total weight per dose) was compressed as the second layer.
  • the caplets were compressed on a Manesty Mark IIA bilayer press, with the following parameters:
  • tooling shape of caplet punch
  • press speed 1200-1600 TPM
  • bilayer thickness (of the whole bilayer caplet) 0.226′′ to 0.234′′.
  • the final bilayer caplet had the following composition per dose: TABLE 2 Caplet Composition Ingredient Amount (mg/dose) Ibuprofen USP 200 Diphenhydramine Citrate USP 38 Calcium Stearate 0.0050 Croscarmellose Sodium 10.0 Glyceryl Behenate NF 3.00 Lactose NF, Monhydrate Spray Dried 90.0 Microcrystalline Cellulose NF 60.6 (EMCOCEL TM 50 M) Silicon Dioxide Colloidal NF AEROSIL 200 4.90 Sodium Lauryl Sulfate LX100 NF 0.500 Sodium Starch Glycolate NF 3.00 Starch Corn 78.9 Starch Pregelatinized NF-1551 40.8 Starch Purity 826 Nat'l NF 7.00 Stearic Acid NF, Powder, Food Grade 1.80 FD&C Blue #2 Alum. Lake 35%-42% 0.0550 Opadry II Blue 49B10882 26.9
  • the ibuprofen/diphenhydramine combination group showed improvement over all the other groups for cumulative percent asleep at 60 minutes, ease of falling asleep, duration of sleep, and global evaluation.
  • the results for duration of sleep were surprising because the combination showed a synergistic effect, resulting in scores higher than the combined scores of diphenhydramine and ibuprofen.
  • the differences between the ibuprofen/diphenhydramine group and the ibuprofen group alone were not significant, probably due to the sample size.
  • Example 1 This study was conducted in a similar manner to Example 1.
  • the diphenhydramine group was omitted, because, as Example 1 demonstrated, it did not provide adequate treatment for study purposes, especially as the patients were experiencing post-surgical pain. Additionally, the effects of diphenhydramine on sleep are known and do not require further study.
  • the combination group received a total dose of 400 mg ibuprofen and 50 mg diphenhydramine in a two combination soft gelatin capsules.
  • the ibuprofen group received 400 mg total dose in two soft gelatin capsules.
  • the placebo group also received soft gelatin capsules.
  • the trial was conducted as a randomized, stratified (by baseline pain and gender), inpatient, placebo controlled, partial factorial, single dose, double blind, parallel group, single center trial. Following oral surgery, patients were kept at the clinic site overnight. Study medications were dispenses when patients experienced pain at a moderate level or greater, and when it was between about 6:30 and 8:00 p.m. (3 hours prior to the patient's usual bedtime). Patients were required to go to sleep after receiving study medication.
  • each interaction was generally significant (p ⁇ 0.15), it was retained in the final model.
  • each level of the stratifying variable were to be weighted equally (consistent with the ANOVA models).
  • Ninety-five percent confidence intervals for the median time to sleep and median time to rescue medication were derived.
  • the actual and cumulative proportion of subjects asleep at each observation time point and the cumulative proportion of subjects who took rescue medication by each observation time point were analyzed by the Cochran-Mantel-Haenszel test controlling for baseline PSR and gender.
  • the combination was better than ibuprofen alone for most sleep assessment parameters. This difference was statistically significant for duration of sleep and marginally significant for percent requiring rescue medication. The combination allowed patients to sleep significantly longer, providing an important improvement in therapy. It was surprising that ibuprofen impacted sleep at the end of the night, i.e., duration of sleep, because its plasma levels fall after 4 to 6 hours. Again, cumulative percent asleep measured the effect of the drug early in the night, and due to diphenhydramine's slower pharmacokinetic profile, the combination group was no better than the ibuprofen group. A graphical representation of these data are shown in FIGS. 4 - 12 .
  • the patients were assessed for duration of sleep, cumulative percent of subjects asleep at 60 minutes post-dosing (based on observed sleep latency assessments). They were also assessed for pain using SPRID2 (time-weighted sum of pain relief and pain intensity differences from baseline over 0-2 hours). Sleep latency (observer based), ease of falling asleep, and global evaluation of sleep were also used. Pain intensity difference combined with pain relief scores (PRID) at 90 and 120 minutes post-dosing, and global evaluation of the study medication as a pain reliever, as well as time to rescue medication were assessed.
  • SPRID2 time-weighted sum of pain relief and pain intensity differences from baseline over 0-2 hours. Sleep latency (observer based), ease of falling asleep, and global evaluation of sleep were also used. Pain intensity difference combined with pain relief scores (PRID) at 90 and 120 minutes post-dosing, and global evaluation of the study medication as a pain reliever, as well as time to rescue medication were assessed.
  • the secondary end points were assessed, at the 0.05 level of significance, in a similar sequential order.
  • the primary analysis of efficacy was based on the intent-to-treat (ITT) population, which included all randomized subjects who took study medication and had at least one post-baseline (sleep and pain) efficacy assessment.
  • the combination of ibuprofen and diphenhydramine was statistically superior to ibuprofen alone for duration of sleep, and better for global assessment of the study medication as a sleep-aid and for the percent requiring rescue medication.
  • the combination again, allows patients to sleep significantly longer than ibuprofen alone.
  • the combination may have been worse for pain treatment because the single-entity soft gelatin capsule has faster release/absorption pharmacokinetics.
  • the absorption profile for the combination is different from the single-entity ibuprofen soft gelatin capsule.
  • This study was a single center, in patient, single dose, randomized (stratified by gender and baseline pain severity), double blind, parallel group, placebo controlled dose-response study. Subjects had undergone oral surgery and were housed at the clinic site overnight. They were required to go to bed at least 3 hours earlier than usual. Each active drug versus placebo was assigned in the ratio of 3:3:1. The 284 patients were assigned to the following groups: 41 to placebo, 120 to the single dose, and 123 to the double dose. The treatment groups were also comparable with respect to the surgical procedure characteristics, except for the trauma rating: there was a higher percentage of subjects who received a double does whose trauma was “severe” compared to the other groups (35.8% vs. ⁇ 22%). Approximately 59% of the subjects had moderate baseline pain, while 41% were severe.
  • the double dose was better at promoting sleep and treating pain than the single dose although not statistically significantly different.
  • the double dose was significantly better than the single dose for duration of sleep (FIG. 23).
  • the SPRID2 scores in the same groups were 1.7, 8.2, and 9.2, respectively (FIG. 25).
  • the PRID scores were significantly better for the double dose group (FIG. 26).
  • TOTPAR is an assessment of pain relief: PRR scores were plotted over time, and the area under the curve was determined.
  • Ibuprofen Diphenhydramine Diphenhydramine Patient (mg) HCl (mg) Citrate (mg) Formulation 1 100 12.5 0 PEG soft gelatin capsule 2 100 12.5 0 bilayer tablet 3 100 0 19 PEG soft gelatin capsule 4 100 0 19 bilayer tablet 5 200 25 0 PEG soft gelatin capsule 6 200 25 0 bilayer tablet 7 200 0 38 PEG soft gelatin capsule 8 200 0 38 bilayer tablet 9 400 50 0 PEG soft gelatin capsule 10 400 50 0 bilayer tablet 11 400 0 76 PEG soft gelatin capsule 12 400 0 76 bilayer tablet 13 600 75 0 PEG soft gelatin capsule 14 600 75 0 bilayer tablet 15 600 0 75 PEG soft gelatin capsule 16 600 0 75 bilayer tablet 17 800 100 0 PEG soft gelatin capsule 18 800 100 0 bilayer tablet 19 800
  • Patients suffering from pain associated sleep disturbances are given ibuprofen and diphenhydramine in a single formulation designed to prevent interactions between the compounds, according to the following table.
  • Appropriate diphenhydramine citrate amounts are substituted easily for the diphenhydramine HCl, and either PEG soft gelatin capsules or bilayer tablets are effective.
  • Patient Ibuprofen Diphenhydramine Patient Characteristics (mg) HCl (mg) Formulation A 90 lbs 100 25 PEG soft gelatin capsule B 150 lbs 400 50 PEG soft gelatin capsule C 250 lbs 600 75 PEG soft gelatin capsule D child 100 12.5 PEG soft gelatin capsule E adult 400 50 PEG soft gelatin capsule F elderly or 100 25 PEG soft medication gelatin sensitive capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/046,727 2001-01-19 2002-01-17 Treatment of sleep disturbances Abandoned US20020177626A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/046,727 US20020177626A1 (en) 2001-01-19 2002-01-17 Treatment of sleep disturbances
US12/082,342 US8263647B2 (en) 2001-01-19 2008-04-10 Treatment of sleep disturbances
US13/584,054 US8883849B2 (en) 2001-01-19 2012-08-13 Treatment of sleep disturbances
US14/504,159 US9155718B2 (en) 2001-01-19 2014-10-01 Treatment of sleep disturbances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26238701P 2001-01-19 2001-01-19
US10/046,727 US20020177626A1 (en) 2001-01-19 2002-01-17 Treatment of sleep disturbances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/082,342 Continuation US8263647B2 (en) 2001-01-19 2008-04-10 Treatment of sleep disturbances

Publications (1)

Publication Number Publication Date
US20020177626A1 true US20020177626A1 (en) 2002-11-28

Family

ID=22997281

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/046,727 Abandoned US20020177626A1 (en) 2001-01-19 2002-01-17 Treatment of sleep disturbances
US12/082,342 Expired - Fee Related US8263647B2 (en) 2001-01-19 2008-04-10 Treatment of sleep disturbances
US13/584,054 Expired - Lifetime US8883849B2 (en) 2001-01-19 2012-08-13 Treatment of sleep disturbances
US14/504,159 Expired - Fee Related US9155718B2 (en) 2001-01-19 2014-10-01 Treatment of sleep disturbances

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/082,342 Expired - Fee Related US8263647B2 (en) 2001-01-19 2008-04-10 Treatment of sleep disturbances
US13/584,054 Expired - Lifetime US8883849B2 (en) 2001-01-19 2012-08-13 Treatment of sleep disturbances
US14/504,159 Expired - Fee Related US9155718B2 (en) 2001-01-19 2014-10-01 Treatment of sleep disturbances

Country Status (11)

Country Link
US (4) US20020177626A1 (fr)
EP (1) EP1363608B1 (fr)
JP (2) JP4402882B2 (fr)
AT (1) ATE309797T1 (fr)
CA (1) CA2434484C (fr)
DE (1) DE60207383T2 (fr)
DK (1) DK1363608T3 (fr)
ES (1) ES2251584T3 (fr)
HK (1) HK1060045A1 (fr)
MX (1) MXPA03006364A (fr)
WO (1) WO2002056877A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20070072917A1 (en) * 2003-07-26 2007-03-29 Srz Properties, Inc. Substituted 2-aminotetralin for the treatment of depression
US20070093546A1 (en) * 2003-07-26 2007-04-26 Srz Properties, Inc. Use of rotigotine for the treatment of depression
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US20080227985A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazoles
WO2008117018A2 (fr) * 2007-03-24 2008-10-02 Reckitt Benckiser Healthcare (Uk) Limited Comprimé présentant une stabilité améliorée avec au moins deux ingrédients actifs
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US8017598B2 (en) 2006-05-16 2011-09-13 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
EP2465500A1 (fr) 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Quantités thérapeutiquement efficaces de R(+) et S(-) pramipexole pour une utilisation dans le traitement de la maladie de Parkinson
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9849116B2 (en) 2008-08-19 2017-12-26 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
JP5148801B2 (ja) * 2002-09-09 2013-02-20 エスエス製薬株式会社 催眠用固形製剤
JP2005281268A (ja) * 2004-03-31 2005-10-13 Taiyo Yakuhin Kogyo Kk 経時安定な抗ヒスタミン類固形製剤
JP2008184430A (ja) * 2007-01-30 2008-08-14 Ss Pharmaceut Co Ltd ソフトカプセル
PT2498758T (pt) * 2009-11-13 2018-10-23 Astrazeneca Uk Ltd Formulações de comprimido bicamada
JP5896645B2 (ja) * 2010-08-26 2016-03-30 興和株式会社 ロキソプロフェン又はその塩の含有医薬製剤
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6112765B2 (ja) * 2010-12-13 2017-04-12 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウム及びｄｌ−メチルエフェドリン塩酸塩を含有する固形製剤
JP6110589B2 (ja) * 2010-12-13 2017-04-05 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとクレマスチンフマル酸塩を含有する固形製剤
JP6126780B2 (ja) * 2010-12-13 2017-05-10 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤
CN102488680B (zh) * 2011-12-21 2012-12-26 西南大学 布洛芬苯海拉明分散片及其制备方法
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
WO2019226150A1 (fr) * 2018-05-21 2019-11-28 Wellesley Pharmaceuticals Inc. Composition et méthodes pour traiter des troubles du sommeil
US20210287564A1 (en) 2020-03-16 2021-09-16 Koninklijke Philips N.V. System and method for bed partner mediated sleep disorder treatment program

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401665A (en) * 1981-04-14 1983-08-30 Bristol-Myers Company Sleep-aid composition containing an analgesic and diphenhydramine dihydrogencitrate, and method of use
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US5431916A (en) * 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
US6248347B1 (en) * 1998-04-23 2001-06-19 Nihon Shokuhin Kako Co., Ltd. Calcium assimilation accelerator and calcium-supplementing diet comprising and a method for accelerating calcium assimilation
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
US6287600B1 (en) * 1999-03-22 2001-09-11 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420483A (en) * 1982-07-22 1983-12-13 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4464376A (en) * 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4755532A (en) * 1984-02-08 1988-07-05 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4683243A (en) * 1984-02-08 1987-07-28 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4585783A (en) * 1984-02-08 1986-04-29 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4906625A (en) * 1984-02-08 1990-03-06 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and metyhods of using same
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
WO1992003122A1 (fr) * 1990-08-24 1992-03-05 Gregor Cevc Composition d'application de fines gouttelettes de substances actives
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JPH08325145A (ja) * 1995-05-26 1996-12-10 Sumitomo Pharmaceut Co Ltd 安定なイソプロピルアンチピリン含有製剤
AU7244696A (en) * 1995-09-29 1997-04-17 Lam Pharmaceuticals Inc. Sustained release delivery system and long acting narcotic analgesics and antagonists
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401665A (en) * 1981-04-14 1983-08-30 Bristol-Myers Company Sleep-aid composition containing an analgesic and diphenhydramine dihydrogencitrate, and method of use
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US5512300A (en) * 1992-09-15 1996-04-30 Warner-Lambert Company Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms
US5431916A (en) * 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US6248347B1 (en) * 1998-04-23 2001-06-19 Nihon Shokuhin Kako Co., Ltd. Calcium assimilation accelerator and calcium-supplementing diet comprising and a method for accelerating calcium assimilation
US6287600B1 (en) * 1999-03-22 2001-09-11 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072917A1 (en) * 2003-07-26 2007-03-29 Srz Properties, Inc. Substituted 2-aminotetralin for the treatment of depression
US20070093546A1 (en) * 2003-07-26 2007-04-26 Srz Properties, Inc. Use of rotigotine for the treatment of depression
US8754119B2 (en) 2003-07-26 2014-06-17 Ucb Pharma Gmbh Use of rotigotine for the treatment of depression
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2497472A1 (fr) 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Quantités thérapeutiquement efficaces de R(+) et S(-) pramipexole pour une utilisation dans le traitement de la maladie de Parkinson et leurs compositions pharmaceutiques
US8445474B2 (en) 2006-05-16 2013-05-21 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
EP2497473A1 (fr) 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Quantités thérapeutiquement efficaces de R(+) et S(-) pramipexole pour une utilisation dans le traitement de la maladie de Parkinson et compositions pharmaceutiques correspondantes
US8017598B2 (en) 2006-05-16 2011-09-13 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
EP2465500A1 (fr) 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Quantités thérapeutiquement efficaces de R(+) et S(-) pramipexole pour une utilisation dans le traitement de la maladie de Parkinson
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US10179774B2 (en) 2007-03-14 2019-01-15 Knopp Biosciences Llc Synthesis of chirally purified substituted benzothiazole diamines
US20080227985A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazoles
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
KR101466331B1 (ko) * 2007-03-24 2014-11-27 레킷트 벵키저 헬스케어(유케이)리미티드 적어도 2개의 활성 성분으로 안정성이 개량된 정제
AU2008231626B2 (en) * 2007-03-24 2013-03-07 Reckitt Benckiser Healthcare (Uk) Limited A tablet having improved stability with at least two actives
US20100152173A1 (en) * 2007-03-24 2010-06-17 Huw Jones Tablet Having Improved Stability With At Least Two Actives
WO2008117018A3 (fr) * 2007-03-24 2009-03-12 Reckitt Benckiser Healthcare Comprimé présentant une stabilité améliorée avec au moins deux ingrédients actifs
WO2008117018A2 (fr) * 2007-03-24 2008-10-02 Reckitt Benckiser Healthcare (Uk) Limited Comprimé présentant une stabilité améliorée avec au moins deux ingrédients actifs
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
US9849116B2 (en) 2008-08-19 2017-12-26 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
US10208003B2 (en) 2011-12-22 2019-02-19 Knopp Biosciences Llc Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9956206B2 (en) 2013-02-28 2018-05-01 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10285981B2 (en) 2013-02-28 2019-05-14 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US11612589B2 (en) 2013-07-12 2023-03-28 Areteia Therapeutics, Inc. Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US11026928B2 (en) 2013-07-12 2021-06-08 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US10980783B2 (en) 2013-07-12 2021-04-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US10383856B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US10456381B2 (en) 2013-08-13 2019-10-29 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US10195183B2 (en) 2013-08-13 2019-02-05 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US10028940B2 (en) 2013-08-13 2018-07-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

Also Published As

Publication number Publication date
HK1060045A1 (en) 2004-07-30
DE60207383T2 (de) 2006-08-03
US20090169584A1 (en) 2009-07-02
DE60207383D1 (de) 2005-12-22
ES2251584T3 (es) 2006-05-01
WO2002056877A1 (fr) 2002-07-25
MXPA03006364A (es) 2003-10-06
JP2009203243A (ja) 2009-09-10
EP1363608A1 (fr) 2003-11-26
DK1363608T3 (da) 2006-02-13
US9155718B2 (en) 2015-10-13
US8263647B2 (en) 2012-09-11
JP4402882B2 (ja) 2010-01-20
US20120308483A1 (en) 2012-12-06
CA2434484C (fr) 2011-08-09
EP1363608B1 (fr) 2005-11-16
US20150018421A1 (en) 2015-01-15
JP2004521104A (ja) 2004-07-15
ATE309797T1 (de) 2005-12-15
US8883849B2 (en) 2014-11-11
CA2434484A1 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
US9155718B2 (en) Treatment of sleep disturbances
US20030161879A1 (en) Tablets quickly disintegrating in mouth
CA2583517C (fr) Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption
SA01210740A (ar) تركيب على شكل جرعات تؤخذ عن طريق الفم ممتدة الانطلاق.
RU2153337C2 (ru) Таблетка парацетамола и домперидона с пленочным покрытием
EA000804B1 (ru) Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка
US10842759B2 (en) Pharmaceutical compositions for N-propargylamine derivative
WO2011152875A1 (fr) Forme galénique solide pouvant être mâchée, avalée et effervescente pour une administration orale de principes actifs pharmaceutiques
ZA200309172B (en) Swallow tablet comprising paracetamol.
Dash Solid dosage forms
US20220023198A1 (en) Oral soluble film containing sildenafil citrate
US10098856B2 (en) Alternating sympathomimetic therapy for the treatment of respiratory ailments
KR100697093B1 (ko) 비타민 ｃ 및 감기 치료제를 함유하는 이중정 제형 및 그의제조방법
EP2248516A1 (fr) Compositions pharmaceutiques d'emoxypine à désintégration orale
WO2019018158A1 (fr) Compositions pharmaceutiques
Guggilla Fast dissolving tablets
CN113679687A (zh) 一种复合释药组合物、口崩片组合物和口崩制剂及其应用
UA145352U (uk) Готовий лікарський засіб для симптоматичного лікування або запобігання застуди або грипу
UA146313U (uk) Готовий лікарський засіб для симптоматичного лікування хронічного запору
UA146880U (uk) Готовий лікарський засіб для лікування захворювань шлунково-кишкового тракту
Anees-Ur-Rahaman Formulation and Evaluation of Fast Dissolving Tablets of Anti-Asthmatic Drug
HU220623B1 (hu) Kinetózis kezelésére alkalmas természetes alapú, gyógyhatású készítmény

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COOK, GRAHAM D.;KOCH, TODD S.;GIAMALVA, DAVID H.;AND OTHERS;REEL/FRAME:012886/0903;SIGNING DATES FROM 20020405 TO 20020412

AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COOK, GRAHAM D.;KOCH, TODD S.;GIAMALVA, DAVID H.;AND OTHERS;REEL/FRAME:013086/0186;SIGNING DATES FROM 20020405 TO 20020412

AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOYLE, GERALDINE;REEL/FRAME:015422/0641

Effective date: 20040520

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION